APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine for Human Rabies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Attenuated Vaccine for Human Rabies Market Analysis and Forecast 2026-2032

Report ID 173968250230 December 2025197 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine for Human Rabies Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine for Human Rabies Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine for Human Rabies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine for Human Rabies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine for Human Rabies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Attenuated Vaccine for Human Rabies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Attenuated Vaccine for Human Rabies include Changchun Zhuoyi Biological Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Attenuated Vaccine for Human Rabies, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Attenuated Vaccine for Human Rabies, also provides the sales of main regions and countries. Of the upcoming market potential for Attenuated Vaccine for Human Rabies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Attenuated Vaccine for Human Rabies sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Attenuated Vaccine for Human Rabies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Attenuated Vaccine for Human Rabies sales, projected growth trends, production technology, application and end-user industry.

Attenuated Vaccine for Human Rabies Segment by Company

Changchun Zhuoyi Biological Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Shandong Yidu Biotechnology Co., Ltd

Ningbo Rongan Biopharmaceutical Co., Ltd

Liaoning Yisheng Biopharmaceutical Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Guangzhou Nuocheng Biological Products Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

AstraZeneca

Sanofi Pasteur, Inc

Pfizer Inc

Novartis AG

Merck & Co Inc

GlaxoSmithKline

Cadila Pharmaceuticals Ltd

Attenuated Vaccine for Human Rabies Segment by Type

Vero Cell

Human Diploid Cell

Attenuated Vaccine for Human Rabies Segment by Application

Hospital

Clinic

Attenuated Vaccine for Human Rabies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Attenuated Vaccine for Human Rabies in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Attenuated Vaccine for Human Rabies sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Attenuated Vaccine for Human Rabies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vero Cell Major Manufacturers Table 3. Human Diploid Cell Major Manufacturers Table 4. Global Attenuated Vaccine for Human Rabies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Attenuated Vaccine for Human Rabies Industry Trends Table 8. Attenuated Vaccine for Human Rabies Industry Drivers Table 9. Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges Table 10. Attenuated Vaccine for Human Rabies Industry Restraints Table 11. Global Attenuated Vaccine for Human Rabies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Attenuated Vaccine for Human Rabies Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Attenuated Vaccine for Human Rabies Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2021-2026) Table 15. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2027-2032) Table 16. Global Attenuated Vaccine for Human Rabies Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026) & (K Units) Table 18. Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032) & (K Units) Table 19. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2021-2026) Table 20. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2027-2032) Table 21. Global Attenuated Vaccine for Human Rabies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Attenuated Vaccine for Human Rabies Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2021-2026) Table 25. Global Attenuated Vaccine for Human Rabies Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Attenuated Vaccine for Human Rabies Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Attenuated Vaccine for Human Rabies Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Attenuated Vaccine for Human Rabies Manufacturers, Product Type & Application Table 29. Global Attenuated Vaccine for Human Rabies Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Attenuated Vaccine for Human Rabies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Attenuated Vaccine for Human Rabies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2026) Table 36. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2027-2032) Table 37. Global Attenuated Vaccine for Human Rabies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 39. Global Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 40. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2026) Table 41. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2027-2032) Table 42. Global Attenuated Vaccine for Human Rabies Price by Type (2021-2026) & (US$/Unit) Table 43. Global Attenuated Vaccine for Human Rabies Price by Type (2027-2032) & (US$/Unit) Table 44. Global Attenuated Vaccine for Human Rabies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2026) Table 48. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2027-2032) Table 49. Global Attenuated Vaccine for Human Rabies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 51. Global Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 52. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2026) Table 53. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2027-2032) Table 54. Global Attenuated Vaccine for Human Rabies Price by Application (2021-2026) & (US$/Unit) Table 55. Global Attenuated Vaccine for Human Rabies Price by Application (2027-2032) & (US$/Unit) Table 56. Changchun Zhuoyi Biological Co., Ltd Company Information Table 57. Changchun Zhuoyi Biological Co., Ltd Business Overview Table 58. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 60. Changchun Zhuoyi Biological Co., Ltd Recent Development Table 61. Wuhan Institute of Biological Products Co., Ltd Company Information Table 62. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 63. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 65. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 66. Shandong Yidu Biotechnology Co., Ltd Company Information Table 67. Shandong Yidu Biotechnology Co., Ltd Business Overview Table 68. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 70. Shandong Yidu Biotechnology Co., Ltd Recent Development Table 71. Ningbo Rongan Biopharmaceutical Co., Ltd Company Information Table 72. Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview Table 73. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 75. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Development Table 76. Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information Table 77. Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview Table 78. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 80. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Development Table 81. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 82. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 83. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 85. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 86. Guangzhou Nuocheng Biological Products Co., Ltd Company Information Table 87. Guangzhou Nuocheng Biological Products Co., Ltd Business Overview Table 88. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 90. Guangzhou Nuocheng Biological Products Co., Ltd Recent Development Table 91. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 92. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 93. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 95. Chengdu Kanghua Biological Products Co., Ltd Recent Development Table 96. AstraZeneca Company Information Table 97. AstraZeneca Business Overview Table 98. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio Table 100. AstraZeneca Recent Development Table 101. Sanofi Pasteur, Inc Company Information Table 102. Sanofi Pasteur, Inc Business Overview Table 103. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 105. Sanofi Pasteur, Inc Recent Development Table 106. Pfizer Inc Company Information Table 107. Pfizer Inc Business Overview Table 108. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 110. Pfizer Inc Recent Development Table 111. Novartis AG Company Information Table 112. Novartis AG Business Overview Table 113. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio Table 115. Novartis AG Recent Development Table 116. Merck & Co Inc Company Information Table 117. Merck & Co Inc Business Overview Table 118. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 120. Merck & Co Inc Recent Development Table 121. GlaxoSmithKline Company Information Table 122. GlaxoSmithKline Business Overview Table 123. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio Table 125. GlaxoSmithKline Recent Development Table 126. Cadila Pharmaceuticals Ltd Company Information Table 127. Cadila Pharmaceuticals Ltd Business Overview Table 128. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 130. Cadila Pharmaceuticals Ltd Recent Development Table 131. North America Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 132. North America Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 133. North America Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 134. North America Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 135. North America Attenuated Vaccine for Human Rabies Sales Price by Type (2021-2026) & (US$/Unit) Table 136. North America Attenuated Vaccine for Human Rabies Sales Price by Type (2027-2032) & (US$/Unit) Table 137. North America Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 138. North America Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 139. North America Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 140. North America Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 141. North America Attenuated Vaccine for Human Rabies Sales Price by Application (2021-2026) & (US$/Unit) Table 142. North America Attenuated Vaccine for Human Rabies Sales Price by Application (2027-2032) & (US$/Unit) Table 143. North America Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. North America Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 145. North America Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 146. North America Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 147. North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 148. North America Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 149. North America Attenuated Vaccine for Human Rabies Sales Price by Country (2021-2026) & (US$/Unit) Table 150. North America Attenuated Vaccine for Human Rabies Sales Price by Country (2027-2032) & (US$/Unit) Table 151. United States Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 152. Canada Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 153. Europe Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 154. Europe Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 155. Europe Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 156. Europe Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 157. Europe Attenuated Vaccine for Human Rabies Sales Price by Type (2021-2026) & (US$/Unit) Table 158. Europe Attenuated Vaccine for Human Rabies Sales Price by Type (2027-2032) & (US$/Unit) Table 159. Europe Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 160. Europe Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 161. Europe Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 162. Europe Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 163. Europe Attenuated Vaccine for Human Rabies Sales Price by Application (2021-2026) & (US$/Unit) Table 164. Europe Attenuated Vaccine for Human Rabies Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Europe Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. Europe Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 167. Europe Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 168. Europe Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 169. Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 170. Europe Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 171. Europe Attenuated Vaccine for Human Rabies Sales Price by Country (2021-2026) & (US$/Unit) Table 172. Europe Attenuated Vaccine for Human Rabies Sales Price by Country (2027-2032) & (US$/Unit) Table 173. Germany Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 174. France Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 175. U.K. Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 176. Italy Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 177. Netherlands Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 178. China Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 179. China Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 180. China Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 181. China Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 182. China Attenuated Vaccine for Human Rabies Sales Price by Type (2021-2026) & (US$/Unit) Table 183. China Attenuated Vaccine for Human Rabies Sales Price by Type (2027-2032) & (US$/Unit) Table 184. China Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 185. China Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 186. China Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 187. China Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 188. China Attenuated Vaccine for Human Rabies Sales Price by Application (2021-2026) & (US$/Unit) Table 189. China Attenuated Vaccine for Human Rabies Sales Price by Application (2027-2032) & (US$/Unit) Table 190. Asia Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 191. Asia Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 192. Asia Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 193. Asia Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 194. Asia Attenuated Vaccine for Human Rabies Sales Price by Type (2021-2026) & (US$/Unit) Table 195. Asia Attenuated Vaccine for Human Rabies Sales Price by Type (2027-2032) & (US$/Unit) Table 196. Asia Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 197. Asia Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 198. Asia Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 199. Asia Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 200. Asia Attenuated Vaccine for Human Rabies Sales Price by Application (2021-2026) & (US$/Unit) Table 201. Asia Attenuated Vaccine for Human Rabies Sales Price by Application (2027-2032) & (US$/Unit) Table 202. Asia Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 203. Asia Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 204. Asia Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 205. Asia Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 206. Asia Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 207. Asia Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 208. Asia Attenuated Vaccine for Human Rabies Sales Price by Country (2021-2026) & (US$/Unit) Table 209. Asia Attenuated Vaccine for Human Rabies Sales Price by Country (2027-2032) & (US$/Unit) Table 210. Japan Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 211. South Korea Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 212. India Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 213. Australia Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 214. China Taiwan Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 215. Southeast Asia Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 216. SAMEA Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (US$ Million) Table 217. SAMEA Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (US$ Million) Table 218. SAMEA Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 219. SAMEA Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 220. SAMEA Attenuated Vaccine for Human Rabies Sales Price by Type (2021-2026) & (US$/Unit) Table 221. SAMEA Attenuated Vaccine for Human Rabies Sales Price by Type (2027-2032) & (US$/Unit) Table 222. SAMEA Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (US$ Million) Table 223. SAMEA Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (US$ Million) Table 224. SAMEA Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 225. SAMEA Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 226. SAMEA Attenuated Vaccine for Human Rabies Sales Price by Application (2021-2026) & (US$/Unit) Table 227. SAMEA Attenuated Vaccine for Human Rabies Sales Price by Application (2027-2032) & (US$/Unit) Table 228. SAMEA Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 229. SAMEA Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 230. SAMEA Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 231. SAMEA Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 232. SAMEA Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 233. SAMEA Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 234. SAMEA Attenuated Vaccine for Human Rabies Sales Price by Country (2021-2026) & (US$/Unit) Table 235. SAMEA Attenuated Vaccine for Human Rabies Sales Price by Country (2027-2032) & (US$/Unit) Table 236. Brazil Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 237. Argentina Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 238. Chile Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 239. Colombia Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 240. Peru Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 241. Saudi Arabia Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 242. Israel Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 243. UAE Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 244. Turkey Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 245. Iran Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 246. Egypt Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Table 247. Key Raw Materials Table 248. Raw Materials Key Suppliers Table 249. Attenuated Vaccine for Human Rabies Distributors List Table 250. Attenuated Vaccine for Human Rabies Customers List Table 251. Research Programs/Design for This Report Table 252. Authors List of This Report Table 253. Secondary Sources Table 254. Primary Sources List of Figures Figure 1. Attenuated Vaccine for Human Rabies Image Figure 2. Global Attenuated Vaccine for Human Rabies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine for Human Rabies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vero Cell Image Figure 5. Human Diploid Cell Image Figure 6. Global Attenuated Vaccine for Human Rabies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Attenuated Vaccine for Human Rabies Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Figure 12. Global Attenuated Vaccine for Human Rabies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2021-2032) Figure 15. Global Attenuated Vaccine for Human Rabies Sales (2021-2032) & (K Units) Figure 16. Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Attenuated Vaccine for Human Rabies Sales YoY (2021-2032) & (K Units) Figure 19. Europe Attenuated Vaccine for Human Rabies Sales YoY (2021-2032) & (K Units) Figure 20. China Attenuated Vaccine for Human Rabies Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Attenuated Vaccine for Human Rabies Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales YoY (2021-2032) & (K Units) Figure 23. Global Attenuated Vaccine for Human Rabies Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Attenuated Vaccine for Human Rabies Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Attenuated Vaccine for Human Rabies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2032) Figure 29. Global Attenuated Vaccine for Human Rabies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2032) Figure 32. Global Attenuated Vaccine for Human Rabies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2032) Figure 35. Global Attenuated Vaccine for Human Rabies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2032) Figure 38. North America Attenuated Vaccine for Human Rabies Revenue Share by Type (2021-2032) Figure 39. North America Attenuated Vaccine for Human Rabies Sales Share by Type (2021-2032) Figure 40. North America Attenuated Vaccine for Human Rabies Revenue Share by Application (2021-2032) Figure 41. North America Attenuated Vaccine for Human Rabies Sales Share by Application (2021-2032) Figure 42. North America Attenuated Vaccine for Human Rabies Revenue Share by Country (2021-2032) Figure 43. North America Attenuated Vaccine for Human Rabies Sales Share by Country (2021-2032) Figure 44. Europe Attenuated Vaccine for Human Rabies Revenue Share by Type (2021-2032) Figure 45. Europe Attenuated Vaccine for Human Rabies Sales Share by Type (2021-2032) Figure 46. Europe Attenuated Vaccine for Human Rabies Revenue Share by Application (2021-2032) Figure 47. Europe Attenuated Vaccine for Human Rabies Sales Share by Application (2021-2032) Figure 48. Europe Attenuated Vaccine for Human Rabies Revenue Share by Country (2021-2032) Figure 49. Europe Attenuated Vaccine for Human Rabies Sales Share by Country (2021-2032) Figure 50. China Attenuated Vaccine for Human Rabies Revenue Share by Type (2021-2032) Figure 51. China Attenuated Vaccine for Human Rabies Sales Share by Type (2021-2032) Figure 52. China Attenuated Vaccine for Human Rabies Revenue Share by Application (2021-2032) Figure 53. China Attenuated Vaccine for Human Rabies Sales Share by Application (2021-2032) Figure 54. Asia Attenuated Vaccine for Human Rabies Revenue Share by Type (2021-2032) Figure 55. Asia Attenuated Vaccine for Human Rabies Sales Share by Type (2021-2032) Figure 56. Asia Attenuated Vaccine for Human Rabies Revenue Share by Application (2021-2032) Figure 57. Asia Attenuated Vaccine for Human Rabies Sales Share by Application (2021-2032) Figure 58. Asia Attenuated Vaccine for Human Rabies Revenue Share by Country (2021-2032) Figure 59. Asia Attenuated Vaccine for Human Rabies Sales Share by Country (2021-2032) Figure 60. SAMEA Attenuated Vaccine for Human Rabies Revenue Share by Type (2021-2032) Figure 61. SAMEA Attenuated Vaccine for Human Rabies Sales Share by Type (2021-2032) Figure 62. SAMEA Attenuated Vaccine for Human Rabies Revenue Share by Application (2021-2032) Figure 63. SAMEA Attenuated Vaccine for Human Rabies Sales Share by Application (2021-2032) Figure 64. SAMEA Attenuated Vaccine for Human Rabies Revenue Share by Country (2021-2032) Figure 65. SAMEA Attenuated Vaccine for Human Rabies Sales Share by Country (2021-2032) Figure 66. Attenuated Vaccine for Human Rabies Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Attenuated Vaccine for Human Rabies Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Vero Cell
  • Human Diploid Cell
Applications
  • Hospital
  • Clinic
Companies covered
  • Changchun Zhuoyi Biological Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Shandong Yidu Biotechnology Co., Ltd
  • Ningbo Rongan Biopharmaceutical Co., Ltd
  • Liaoning Yisheng Biopharmaceutical Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd
  • Guangzhou Nuocheng Biological Products Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur, Inc
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline
  • Cadila Pharmaceuticals Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Attenuated Vaccine for Human Rabies Market by Type
  3. 1.2.1 Global Attenuated Vaccine for Human Rabies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vero Cell
  5. 1.2.3 Human Diploid Cell
  6. 1.3 Attenuated Vaccine for Human Rabies Market by Application
  7. 1.3.1 Global Attenuated Vaccine for Human Rabies Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Attenuated Vaccine for Human Rabies Market Dynamics
  1. 2.1 Attenuated Vaccine for Human Rabies Industry Trends
  2. 2.2 Attenuated Vaccine for Human Rabies Industry Drivers
  3. 2.3 Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine for Human Rabies Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Attenuated Vaccine for Human Rabies Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Attenuated Vaccine for Human Rabies Revenue by Region
  3. 3.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Attenuated Vaccine for Human Rabies Revenue by Region (2021-2026)
  5. 3.2.3 Global Attenuated Vaccine for Human Rabies Revenue by Region (2027-2032)
  6. 3.2.4 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Attenuated Vaccine for Human Rabies Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Attenuated Vaccine for Human Rabies Sales by Region
  9. 3.4.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026)
  11. 3.4.3 Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032)
  12. 3.4.4 Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Attenuated Vaccine for Human Rabies Revenue by Manufacturers
  2. 4.1.1 Global Attenuated Vaccine for Human Rabies Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Attenuated Vaccine for Human Rabies Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Attenuated Vaccine for Human Rabies Sales by Manufacturers
  6. 4.2.1 Global Attenuated Vaccine for Human Rabies Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Attenuated Vaccine for Human Rabies Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Attenuated Vaccine for Human Rabies Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Attenuated Vaccine for Human Rabies Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Attenuated Vaccine for Human Rabies Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Attenuated Vaccine for Human Rabies Manufacturers, Product Type & Application
  13. 4.7 Global Attenuated Vaccine for Human Rabies Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Attenuated Vaccine for Human Rabies Market CR5 and HHI
  16. 4.8.2 2025 Attenuated Vaccine for Human Rabies Tier 1, Tier 2, and Tier 3
5 Attenuated Vaccine for Human Rabies Market by Type
  1. 5.1 Global Attenuated Vaccine for Human Rabies Revenue by Type
  2. 5.1.1 Global Attenuated Vaccine for Human Rabies Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Attenuated Vaccine for Human Rabies Sales by Type
  6. 5.2.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2032)
  9. 5.3 Global Attenuated Vaccine for Human Rabies Price by Type
6 Attenuated Vaccine for Human Rabies Market by Application
  1. 6.1 Global Attenuated Vaccine for Human Rabies Revenue by Application
  2. 6.1.1 Global Attenuated Vaccine for Human Rabies Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Attenuated Vaccine for Human Rabies Sales by Application
  6. 6.2.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2032)
  9. 6.3 Global Attenuated Vaccine for Human Rabies Price by Application
7 Company Profiles
  1. 7.1 Changchun Zhuoyi Biological Co., Ltd
  2. 7.1.1 Changchun Zhuoyi Biological Co., Ltd Company Information
  3. 7.1.2 Changchun Zhuoyi Biological Co., Ltd Business Overview
  4. 7.1.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  6. 7.1.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments
  7. 7.2 Wuhan Institute of Biological Products Co., Ltd
  8. 7.2.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  9. 7.2.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  10. 7.2.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  12. 7.2.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  13. 7.3 Shandong Yidu Biotechnology Co., Ltd
  14. 7.3.1 Shandong Yidu Biotechnology Co., Ltd Company Information
  15. 7.3.2 Shandong Yidu Biotechnology Co., Ltd Business Overview
  16. 7.3.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  18. 7.3.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments
  19. 7.4 Ningbo Rongan Biopharmaceutical Co., Ltd
  20. 7.4.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
  21. 7.4.2 Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview
  22. 7.4.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  24. 7.4.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments
  25. 7.5 Liaoning Yisheng Biopharmaceutical Co., Ltd
  26. 7.5.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
  27. 7.5.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview
  28. 7.5.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  30. 7.5.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments
  31. 7.6 Lanzhou Institute of Biological Products Co., Ltd
  32. 7.6.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  33. 7.6.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  34. 7.6.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  36. 7.6.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  37. 7.7 Guangzhou Nuocheng Biological Products Co., Ltd
  38. 7.7.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
  39. 7.7.2 Guangzhou Nuocheng Biological Products Co., Ltd Business Overview
  40. 7.7.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  42. 7.7.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments
  43. 7.8 Chengdu Kanghua Biological Products Co., Ltd
  44. 7.8.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  45. 7.8.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  46. 7.8.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  48. 7.8.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 Sanofi Pasteur, Inc
  56. 7.10.1 Sanofi Pasteur, Inc Company Information
  57. 7.10.2 Sanofi Pasteur, Inc Business Overview
  58. 7.10.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
  60. 7.10.5 Sanofi Pasteur, Inc Recent Developments
  61. 7.11 Pfizer Inc
  62. 7.11.1 Pfizer Inc Company Information
  63. 7.11.2 Pfizer Inc Business Overview
  64. 7.11.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
  66. 7.11.5 Pfizer Inc Recent Developments
  67. 7.12 Novartis AG
  68. 7.12.1 Novartis AG Company Information
  69. 7.12.2 Novartis AG Business Overview
  70. 7.12.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
  72. 7.12.5 Novartis AG Recent Developments
  73. 7.13 Merck & Co Inc
  74. 7.13.1 Merck & Co Inc Company Information
  75. 7.13.2 Merck & Co Inc Business Overview
  76. 7.13.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
  78. 7.13.5 Merck & Co Inc Recent Developments
  79. 7.14 GlaxoSmithKline
  80. 7.14.1 GlaxoSmithKline Company Information
  81. 7.14.2 GlaxoSmithKline Business Overview
  82. 7.14.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
  84. 7.14.5 GlaxoSmithKline Recent Developments
  85. 7.15 Cadila Pharmaceuticals Ltd
  86. 7.15.1 Cadila Pharmaceuticals Ltd Company Information
  87. 7.15.2 Cadila Pharmaceuticals Ltd Business Overview
  88. 7.15.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  90. 7.15.5 Cadila Pharmaceuticals Ltd Recent Developments
8 North America
  1. 8.1 North America Attenuated Vaccine for Human Rabies Market Size by Type
  2. 8.1.1 North America Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  3. 8.1.2 North America Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  4. 8.1.3 North America Attenuated Vaccine for Human Rabies Price by Type (2021-2032)
  5. 8.2 North America Attenuated Vaccine for Human Rabies Market Size by Application
  6. 8.2.1 North America Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  7. 8.2.2 North America Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  8. 8.2.3 North America Attenuated Vaccine for Human Rabies Price by Application (2021-2032)
  9. 8.3 North America Attenuated Vaccine for Human Rabies Market Size by Country
  10. 8.3.1 North America Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Attenuated Vaccine for Human Rabies Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Attenuated Vaccine for Human Rabies Market Size by Type
  2. 9.1.1 Europe Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  3. 9.1.2 Europe Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  4. 9.1.3 Europe Attenuated Vaccine for Human Rabies Price by Type (2021-2032)
  5. 9.2 Europe Attenuated Vaccine for Human Rabies Market Size by Application
  6. 9.2.1 Europe Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  7. 9.2.2 Europe Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  8. 9.2.3 Europe Attenuated Vaccine for Human Rabies Price by Application (2021-2032)
  9. 9.3 Europe Attenuated Vaccine for Human Rabies Market Size by Country
  10. 9.3.1 Europe Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Attenuated Vaccine for Human Rabies Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Attenuated Vaccine for Human Rabies Market Size by Type
  2. 10.1.1 China Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  3. 10.1.2 China Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  4. 10.1.3 China Attenuated Vaccine for Human Rabies Price by Type (2021-2032)
  5. 10.2 China Attenuated Vaccine for Human Rabies Market Size by Application
  6. 10.2.1 China Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  7. 10.2.2 China Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  8. 10.2.3 China Attenuated Vaccine for Human Rabies Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Attenuated Vaccine for Human Rabies Market Size by Type
  2. 11.1.1 Asia Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  3. 11.1.2 Asia Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  4. 11.1.3 Asia Attenuated Vaccine for Human Rabies Price by Type (2021-2032)
  5. 11.2 Asia Attenuated Vaccine for Human Rabies Market Size by Application
  6. 11.2.1 Asia Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  7. 11.2.2 Asia Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  8. 11.2.3 Asia Attenuated Vaccine for Human Rabies Price by Application (2021-2032)
  9. 11.3 Asia Attenuated Vaccine for Human Rabies Market Size by Country
  10. 11.3.1 Asia Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Attenuated Vaccine for Human Rabies Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Attenuated Vaccine for Human Rabies Market Size by Type
  2. 12.1.1 SAMEA Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Attenuated Vaccine for Human Rabies Price by Type (2021-2032)
  5. 12.2 SAMEA Attenuated Vaccine for Human Rabies Market Size by Application
  6. 12.2.1 SAMEA Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Attenuated Vaccine for Human Rabies Price by Application (2021-2032)
  9. 12.3 SAMEA Attenuated Vaccine for Human Rabies Market Size by Country
  10. 12.3.1 SAMEA Attenuated Vaccine for Human Rabies Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Attenuated Vaccine for Human Rabies Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Attenuated Vaccine for Human Rabies Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Attenuated Vaccine for Human Rabies Value Chain Analysis
  2. 13.1.1 Attenuated Vaccine for Human Rabies Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Attenuated Vaccine for Human Rabies Production Mode & Process
  6. 13.2 Attenuated Vaccine for Human Rabies Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Attenuated Vaccine for Human Rabies Distributors
  9. 13.2.3 Attenuated Vaccine for Human Rabies Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst